# Immunotherapy Before and After Surgery

> **NCT06765902** · PHASE2 · WITHDRAWN · sponsor: **ImmunityBio, Inc.**

## Conditions studied

- High-risk Prostate Cancer

## Interventions

- **DRUG:** N-803
- **DRUG:** ETBX-071
- **DRUG:** M-CENK

## Key facts

- **NCT ID:** NCT06765902
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-12-15
- **Primary completion:** 2031-01-31
- **Final completion:** 2031-06-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was redeveloped into a new protocol
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06765902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06765902, "Immunotherapy Before and After Surgery". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06765902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*